Gu X, Gu S, Chen Z, Tong J, Li X, Dong H
World J Hepatol. 2025; 17(2):99046.
PMID: 40027555
PMC: 11866147.
DOI: 10.4254/wjh.v17.i2.99046.
Toghraie F, Bayat M, Hosseini M, Ramezani A
Cell Oncol (Dordr). 2025; .
PMID: 39998754
DOI: 10.1007/s13402-025-01051-y.
Li Y, Liu F, Cai Q, Deng L, OuYang Q, Zhang X
Signal Transduct Target Ther. 2025; 10(1):57.
PMID: 39979279
PMC: 11842613.
DOI: 10.1038/s41392-025-02148-4.
Rivas C, Liu F, Zhang X
Adv Exp Med Biol. 2025; 1464():397-412.
PMID: 39821035
DOI: 10.1007/978-3-031-70875-6_19.
Zuo Q, Kang Y
Adv Exp Med Biol. 2025; 1464():347-370.
PMID: 39821033
DOI: 10.1007/978-3-031-70875-6_17.
Homologous-adhering/targeting cell membrane- and cell-mediated delivery systems: a cancer-catch-cancer strategy in cancer therapy.
Liu C, Gao J, Cheng Y, Zhang S, Fu C
Regen Biomater. 2025; 12:rbae135.
PMID: 39811105
PMC: 11729729.
DOI: 10.1093/rb/rbae135.
Reversal of postoperative breast cancer metastasis by the use of embedded hydrogel.
Yu Z, Chi W, Wang C, Qiu Y, Qiu Z, Zhu W
Am J Transl Res. 2024; 16(11):6991-7015.
PMID: 39678538
PMC: 11645627.
DOI: 10.62347/VZAW2270.
Tumor-related fungi and crosstalk with gut fungi in the tumor microenvironment.
Wang Y, Wang Y, Zhou Y, Feng Y, Sun T, Xu J
Cancer Biol Med. 2024; 21(11).
PMID: 39601429
PMC: 11667784.
DOI: 10.20892/j.issn.2095-3941.2024.0240.
CircMALAT1 promotes the proliferation and metastasis of intrahepatic cholangiocarcinoma via the miR-512-5p/VCAM1 axis.
Zhang M, He M, Bai L, Du F, Xie Y, Li B
Acta Biochim Biophys Sin (Shanghai). 2024; 57(2):223-236.
PMID: 39463204
PMC: 11877140.
DOI: 10.3724/abbs.2024185.
Biomimetic nanocarriers in cancer therapy: based on intercellular and cell-tumor microenvironment communication.
Mengyuan H, Aixue L, Yongwei G, Qingqing C, Huanhuan C, Xiaoyan L
J Nanobiotechnology. 2024; 22(1):604.
PMID: 39370518
PMC: 11456251.
DOI: 10.1186/s12951-024-02835-4.
Dormancy and awakening of cancer cells: the extracellular vesicle-mediated cross-talk between Dr. Jekill and Mr. Hyde.
DAntonio C, Liguori G
Front Immunol. 2024; 15:1441914.
PMID: 39301024
PMC: 11410588.
DOI: 10.3389/fimmu.2024.1441914.
Areca nut-induced metabolic reprogramming and M2 differentiation promote OPMD malignant transformation.
Yuan S, Chan L, Nguyen H, Su C, Chen Y, Chen J
J Exp Clin Cancer Res. 2024; 43(1):233.
PMID: 39160581
PMC: 11334407.
DOI: 10.1186/s13046-024-03163-z.
An update to experimental and clinical aspects of tumor-associated macrophages in cancer development: hopes and pitfalls.
Salmaninejad A, Layeghi S, Falakian Z, Golestani S, Kobravi S, Talebi S
Clin Exp Med. 2024; 24(1):156.
PMID: 39003350
PMC: 11246281.
DOI: 10.1007/s10238-024-01417-w.
Cancer treatments as paradoxical catalysts of tumor awakening in the lung.
Nicolas E, Kosmider B, Cukierman E, Borghaei H, Golemis E, Borriello L
Cancer Metastasis Rev. 2024; 43(4):1165-1183.
PMID: 38963567
PMC: 11554904.
DOI: 10.1007/s10555-024-10196-5.
The adhesion-GPCR ADGRF5 fuels breast cancer progression by suppressing the MMP8-mediated antitumorigenic effects.
Wu Y, Liu H, Sun Z, Liu J, Li K, Fan R
Cell Death Dis. 2024; 15(6):455.
PMID: 38937435
PMC: 11211477.
DOI: 10.1038/s41419-024-06855-8.
Deciphering the performance of macrophages in tumour microenvironment: a call for precision immunotherapy.
Toledo B, Zhu Chen L, Paniagua-Sancho M, Marchal J, Peran M, Giovannetti E
J Hematol Oncol. 2024; 17(1):44.
PMID: 38863020
PMC: 11167803.
DOI: 10.1186/s13045-024-01559-0.
Immune Cell Migration to Cancer.
Ryan A, Kim M, Lim K
Cells. 2024; 13(10.
PMID: 38786066
PMC: 11120175.
DOI: 10.3390/cells13100844.
Single cell transcriptomic analyses reveal diverse and dynamic changes of distinct populations of lung interstitial macrophages in hypoxia-induced pulmonary hypertension.
Kumar S, Mickael C, Kumar R, Prasad R, Campbell N, Zhang H
Front Immunol. 2024; 15:1372959.
PMID: 38690277
PMC: 11059952.
DOI: 10.3389/fimmu.2024.1372959.
Macrophage membrane-camouflaged pH-sensitive nanoparticles for targeted therapy of oral squamous cell carcinoma.
Yang L, Li H, Luo A, Zhang Y, Chen H, Zhu L
J Nanobiotechnology. 2024; 22(1):168.
PMID: 38610015
PMC: 11015647.
DOI: 10.1186/s12951-024-02433-4.
Clinical variables associated with immune checkpoint inhibitor outcomes in patients with metastatic urothelial carcinoma: a multicentre retrospective cohort study.
Labidi S, Meti N, Barua R, Li M, Riromar J, Jiang D
BMJ Open. 2024; 14(3):e081480.
PMID: 38553056
PMC: 10982788.
DOI: 10.1136/bmjopen-2023-081480.